In contrast, in pediatric cases with severe, life-threatening early-onset obesity, the primary achievement may be halting relentless disease progression and weight gain, a milestone in itself, alongside improvements in insulin sensitivity, liver enzymes, and notably, behavioral domains such as concentration and emotional stability
The unique advantage of retatrutide, its ability to increase energy expenditure and fat oxidation beyond what GLP-1/GIP alone achieve, may depend on reaching peak concentrations that only weekly dosing reliably provides
Had current treatment with or history of treatment with (within 3 months prior to screening) medications that may cause significant weight gain, including, but not limited to, tricyclic antidepressants, atypical antipsychotics and mood stabilizers
We also weigh how this therapy fits alongside the rest of care